{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:32Z","timestamp":1792783352753,"version":"4.5.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National Natural Science Foundation of China","award":["82503528"],"award-info":[{"award-number":["82503528"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Basic Research Program of Jiangsu","award":["BK20250568"],"award-info":[{"award-number":["BK20250568"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01837-9","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:07:18Z","timestamp":1790572038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unraveling the Mechanisms of Chemoresistance in Gastric Cancer: Insights and Emerging Research Strategies"],"prefix":"10.1007","volume":"28","author":[{"given":"Benshuai","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7235-5439","authenticated-orcid":false,"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"1837_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.21147\/j.issn.1000-9604.2020.06.03","volume":"32","author":"L Yang","year":"2020","unstructured":"Yang L, Ying X, Liu S, Lyu G, Xu Z, Zhang X, Li H, Li Q, Wang N, Ji J. Gastric cancer: Epidemiology, risk factors and prevention strategies. Chin J Cancer Res. 2020;32:695\u2013704.","journal-title":"Chin J Cancer Res"},{"key":"1837_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41571-023-00747-0","volume":"20","author":"AP Thrift","year":"2023","unstructured":"Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20:338\u201349.","journal-title":"Nat Rev Clin Oncol"},{"key":"1837_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13046-018-0935-8","volume":"37","author":"J Wu","year":"2018","unstructured":"Wu J, Chen S, Liu H, Zhang Z, Ni Z, Chen J, Yang Z, Nie Y, Fan D. Tunicamycin specifically aggravates ER stress and overcomes chemoresistance in multidrug-resistant gastric cancer cells by inhibiting N-glycosylation. J Exp Clin Cancer Res. 2018;37:272.","journal-title":"J Exp Clin Cancer Res"},{"key":"1837_CR4","doi-asserted-by":"publisher","first-page":"100913","DOI":"10.1016\/j.drup.2022.100913","volume":"66","author":"J Wu","year":"2023","unstructured":"Wu J, Zhou Z, Li J, Liu H, Zhang H, Zhang J, Huang W, He Y, Zhu S, Huo M, Liu M, Zhang C. CHD4 promotes acquired chemoresistance and tumor progression by activating the MEK\/ERK axis. Drug Resist Updat. 2023;66:100913.","journal-title":"Drug Resist Updat"},{"key":"1837_CR5","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1158\/1541-7786.MCR-23-0034","volume":"21","author":"LJ Stanland","year":"2023","unstructured":"Stanland LJ, Ang HX, Hoj JP, Chu Y, Tan P, Wood KC, Luftig MA. CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer. Mol Cancer Res. 2023;21:1148\u201362.","journal-title":"Mol Cancer Res"},{"key":"1837_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10120-019-01010-1","volume":"23","author":"H Moro","year":"2020","unstructured":"Moro H, Hattori N, Nakamura Y, Kimura K, Imai T, Maeda M, Yashiro M, Ushijima T. Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways. Gastric Cancer. 2020;23:105\u201315.","journal-title":"Gastric Cancer"},{"key":"1837_CR7","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1080\/15548627.2021.1901204","volume":"17","author":"Y Luo","year":"2021","unstructured":"Luo Y, Zheng S, Wu Q, Wu J, Zhou R, Wang C, Wu Z, Rong X, Huang N, Sun L, Bin J, Liao Y, Shi M, Liao W. Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation. Autophagy. 2021;17:4083\u2013101.","journal-title":"Autophagy"},{"key":"1837_CR8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12906-020-02983-8","volume":"20","author":"W Huang","year":"2020","unstructured":"Huang W, Tang H, Wen F, Lu X, Li Q, Shu P. Jianpi-yangwei decoction inhibits DNA damage repair in the drug resistance of gastric cancer by reducing FEN1 expression. BMC Complement Med Ther. 2020;20:196.","journal-title":"BMC Complement Med Ther"},{"key":"1837_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.7150\/ijms.102976","volume":"22","author":"Q Liu","year":"2025","unstructured":"Liu Q, Song Y, Su J, Yang S, Lian Q, Wang T, Wei H, Fang J. PUF60 Promotes Chemoresistance Through Drug Efflux and Reducing Apoptosis in Gastric Cancer. Int J Med Sci. 2025;22:269\u201382.","journal-title":"Int J Med Sci"},{"key":"1837_CR10","doi-asserted-by":"crossref","unstructured":"Rao X, Zhang C, Luo H, Zhang J, Zhuang Z, Liang Z, Wu X. Targeting Gastric Cancer Stem Cells to Enhance Treatment Response. Volume 11. Cells; 2022.","DOI":"10.3390\/cells11182828"},{"key":"1837_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13046-016-0487-8","volume":"36","author":"J Xu","year":"2017","unstructured":"Xu J, Liu D, Niu H, Zhu G, Xu Y, Ye D, Li J, Zhang Q. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN\/Akt signaling pathway in gastric cancer. J Exp Clin Cancer Res. 2017;36:19.","journal-title":"J Exp Clin Cancer Res"},{"key":"1837_CR12","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1038\/sj.onc.1210084","volume":"26","author":"Y Basaki","year":"2007","unstructured":"Basaki Y, Hosoi F, Oda Y, Fotovati A, Maruyama Y, Oie S, Ono M, Izumi H, Kohno K, Sakai K, Shimoyama T, Nishio K, Kuwano M. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene. 2007;26:2736\u201346.","journal-title":"Oncogene"},{"key":"1837_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321.","journal-title":"Lancet Oncol"},{"key":"1837_CR14","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/0008-5472.CAN-15-2361","volume":"76","author":"D Mo","year":"2016","unstructured":"Mo D, Fang H, Niu K, Liu J, Wu M, Li S, Zhu T, Aleskandarany MA, Arora A, Lobo DN, Madhusudan S, Balajee AS, Chi Z, Zhao Y. Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1 Signaling Pathway. Cancer Res. 2016;76:3057\u201366.","journal-title":"Cancer Res"},{"key":"1837_CR15","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.7150\/thno.69424","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang C, Xu C, Gao X, Yao Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 2022;12:2115\u201332.","journal-title":"Theranostics"},{"key":"1837_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u201378.","journal-title":"Eur J Pharmacol"},{"key":"1837_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","volume":"18","author":"RJ Kathawala","year":"2015","unstructured":"Kathawala RJ, Gupta P, Ashby CR Jr., Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat. 2015;18:1\u201317.","journal-title":"Drug Resist Updat"},{"key":"1837_CR18","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869\u201383.","journal-title":"Oncogene"},{"key":"1837_CR19","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S0006-2952(02)01156-5","volume":"64","author":"S Labialle","year":"2002","unstructured":"Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol. 2002;64:943\u20138.","journal-title":"Biochem Pharmacol"},{"key":"1837_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.biocel.2011.12.009","volume":"44","author":"D Fu","year":"2012","unstructured":"Fu D, Arias IM. Intracellular trafficking of P-glycoprotein. Int J Biochem Cell Biol. 2012;44:461\u20134.","journal-title":"Int J Biochem Cell Biol"},{"key":"1837_CR21","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0021-9258(19)75806-2","volume":"262","author":"K Ueda","year":"1987","unstructured":"Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem. 1987;262:505\u20138.","journal-title":"J Biol Chem"},{"key":"1837_CR22","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","volume":"22","author":"ZH Siddik","year":"2003","unstructured":"Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265\u201379.","journal-title":"Oncogene"},{"key":"1837_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41420-022-01161-8","volume":"8","author":"H Wang","year":"2022","unstructured":"Wang H, Liu M, Zeng X, Zheng Y, Wang Y, Zhou Y. Cell death affecting the progression of gastric cancer. Cell Death Discov. 2022;8:377.","journal-title":"Cell Death Discov"},{"key":"1837_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41422-019-0164-5","volume":"29","author":"D Tang","year":"2019","unstructured":"Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res. 2019;29:347\u201364.","journal-title":"Cell Res"},{"key":"1837_CR25","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.3892\/or.2015.3898","volume":"33","author":"XL Ye","year":"2015","unstructured":"Ye XL, Zhao YR, Weng GB, Chen YC, Wei XN, Shao JP, Ji H. IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance. Oncol Rep. 2015;33:2746\u201352.","journal-title":"Oncol Rep"},{"key":"1837_CR26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/ddr.21650","volume":"81","author":"F Xiao","year":"2020","unstructured":"Xiao F, Ouyang B, Zou J, Yang Y, Yi L, Yan H. Trim14 promotes autophagy and chemotherapy resistance of gastric cancer cells by regulating AMPK\/mTOR pathway. Drug Dev Res. 2020;81:544\u201350.","journal-title":"Drug Dev Res"},{"key":"1837_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.canlet.2004.11.013","volume":"223","author":"XX Cheng","year":"2005","unstructured":"Cheng XX, Wang ZC, Chen XY, Sun Y, Kong QY, Liu J, Li H. Correlation of Wnt-2 expression and beta-catenin intracellular accumulation in Chinese gastric cancers: relevance with tumour dissemination. Cancer Lett. 2005;223:339\u201347.","journal-title":"Cancer Lett"},{"key":"1837_CR28","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1038\/s41418-022-01008-w","volume":"29","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zheng L, Shang W, Yang Z, Li T, Liu F, Shao W, Lv L, Chai L, Qu L, Xu Q, Du J, Liang X, Zeng J, Jia J. Wnt\/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer. Cell Death Differ. 2022;29:2190\u2013202.","journal-title":"Cell Death Differ"},{"key":"1837_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-020-01185-7","volume":"19","author":"L Wei","year":"2020","unstructured":"Wei L, Sun J, Zhang N, Zheng Y, Wang X, Lv L, Liu J, Xu Y, Shen Y, Yang M. Noncoding RNAs in gastric cancer: implications for drug resistance. Mol Cancer. 2020;19:62.","journal-title":"Mol Cancer"},{"key":"1837_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3748\/wjg.v27.i6.487","volume":"27","author":"P Deng","year":"2021","unstructured":"Deng P, Sun M, Zhao WY, Hou B, Li K, Zhang T, Gu F. Circular RNA circVAPA promotes chemotherapy drug resistance in gastric cancer progression by regulating miR-125b-5p\/STAT3 axis. World J Gastroenterol. 2021;27:487\u2013500.","journal-title":"World J Gastroenterol"},{"key":"1837_CR31","doi-asserted-by":"publisher","first-page":"767590","DOI":"10.3389\/fgene.2021.767590","volume":"12","author":"R Zhang","year":"2021","unstructured":"Zhang R, Zhao H, Yuan H, Wu J, Liu H, Sun S, Zhang Z, Wang J. CircARVCF Contributes to Cisplatin Resistance in Gastric Cancer by Altering miR-1205 and FGFR1. Front Genet. 2021;12:767590.","journal-title":"Front Genet"},{"key":"1837_CR32","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.bbrc.2020.03.156","volume":"526","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Miao Y, Fu Q, Hu H, Chen H, Zeng A, Jin Y, Jiang Y, Qian L, Wu L, Xu L, Wang G, Qiu L, Huang X, Xia Y. CircRNACCDC66 regulates cisplatin resistance in gastric cancer via the miR-618\/BCL2 axis. Biochem Biophys Res Commun. 2020;526:713\u201320.","journal-title":"Biochem Biophys Res Commun"},{"key":"1837_CR33","doi-asserted-by":"crossref","unstructured":"Huang XX, Zhang Q, Hu H, Jin Y, Zeng AL, Xia YB, Xu L. A novel circular RNA circFN1 enhances cisplatin resistance in gastric cancer via sponging miR-182-5p. J Cell Biochem, (2020).","DOI":"10.1002\/jcb.29641"},{"key":"1837_CR34","first-page":"347","volume":"36","author":"W Yao","year":"2021","unstructured":"Yao W, Guo P, Mu Q, Wang Y. Circ-PVT1 Contributes to Cisplatin Resistance by Regulating Autophagy, Invasion, and Apoptosis Via miR-30a-5p\/YAP1 Axis in Gastric Cancer Cells. Cancer Biother Radiopharm. 2021;36:347\u201359.","journal-title":"Cancer Biother Radiopharm"},{"key":"1837_CR35","doi-asserted-by":"publisher","first-page":"10505","DOI":"10.2147\/CMAR.S272324","volume":"12","author":"S Liu","year":"2020","unstructured":"Liu S, Wu M, Peng M. Circ_0000260 Regulates the Development and Deterioration of Gastric Adenocarcinoma with Cisplatin Resistance by Upregulating MMP11 via Targeting MiR-129-5p. Cancer Manag Res. 2020;12:10505\u201319.","journal-title":"Cancer Manag Res"},{"key":"1837_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12943-019-0969-3","volume":"18","author":"X Huang","year":"2019","unstructured":"Huang X, Li Z, Zhang Q, Wang W, Li B, Wang L, Xu Z, Zeng A, Zhang X, Zhang X, He Z, Li Q, Sun G, Wang S, Li Q, Wang L, Zhang L, Xu H, Xu Z. Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Mol Cancer. 2019;18:71.","journal-title":"Mol Cancer"},{"key":"1837_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12935-019-0737-x","volume":"19","author":"M Xue","year":"2019","unstructured":"Xue M, Li G, Fang X, Wang L, Jin Y, Zhou Q. hsa_circ_0081143 promotes cisplatin resistance in gastric cancer by targeting miR-646\/CDK6 pathway. Cancer Cell Int. 2019;19:25.","journal-title":"Cancer Cell Int"},{"key":"1837_CR38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12943-020-01270-x","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng L, Sang H, Wei S, Li Y, Jin D, Zhu X, Li X, Dang Y, Zhang G. circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR-142-3p\/ROCK2. Mol Cancer. 2020;19:156.","journal-title":"Mol Cancer"},{"key":"1837_CR39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13046-020-01758-w","volume":"39","author":"G Sun","year":"2020","unstructured":"Sun G, Li Z, He Z, Wang W, Wang S, Zhang X, Cao J, Xu P, Wang H, Huang X, Xia Y, Lv J, Xuan Z, Jiang T, Fang L, Yang J, Zhang D, Xu H, Xu Z. Circular RNA MCTP2 inhibits cisplatin resistance in gastric cancer by miR-99a-5p-mediated induction of MTMR3 expression. J Exp Clin Cancer Res. 2020;39:246.","journal-title":"J Exp Clin Cancer Res"},{"key":"1837_CR40","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/jcb.29370","volume":"121","author":"H Li","year":"2020","unstructured":"Li H, Ma X, Yang D, Suo Z, Dai R, Liu C. PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2. J Cell Biochem. 2020;121:1353\u201361.","journal-title":"J Cell Biochem"},{"key":"1837_CR41","doi-asserted-by":"publisher","first-page":"109255","DOI":"10.1016\/j.biopha.2019.109255","volume":"118","author":"Y Guo","year":"2019","unstructured":"Guo Y, Yue P, Wang Y, Chen G, Li Y. PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128\/ZEB1 axis. Biomed Pharmacother. 2019;118:109255.","journal-title":"Biomed Pharmacother"},{"key":"1837_CR42","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.biopha.2017.04.111","volume":"92","author":"X Zhang","year":"2017","unstructured":"Zhang X, Bo P, Liu L, Zhang X, Li J. Overexpression of long non-coding RNA GHET1 promotes the development of multidrug resistance in gastric cancer cells. Biomed Pharmacother. 2017;92:580\u20135.","journal-title":"Biomed Pharmacother"},{"key":"1837_CR43","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3892\/or.2016.4771","volume":"36","author":"WG Lan","year":"2016","unstructured":"Lan WG, Xu DH, Xu C, Ding CL, Ning FL, Zhou YL, Ma LB, Liu CM, Han X. Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol Rep. 2016;36:263\u201370.","journal-title":"Oncol Rep"},{"key":"1837_CR44","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1016\/j.ijbiomac.2017.10.154","volume":"107","author":"C Cheng","year":"2018","unstructured":"Cheng C, Qin Y, Zhi Q, Wang J, Qin C. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K\/Akt and Wnt\/\u03b2-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 2018;107:2620\u20139.","journal-title":"Int J Biol Macromol"},{"key":"1837_CR45","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1159\/000495499","volume":"51","author":"L Zeng","year":"2018","unstructured":"Zeng L, Liao Q, Zou Z, Wen Y, Wang J, Liu C, He Q, Weng N, Zeng J, Tang H, Fang R, Lei Z, Tang Z, Yang X, Cui S. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K\/AKT\/mTOR Signaling Pathway. Cell Physiol Biochem. 2018;51:1221\u201336.","journal-title":"Cell Physiol Biochem"},{"key":"1837_CR46","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1080\/09168451.2018.1431518","volume":"82","author":"W Xu","year":"2018","unstructured":"Xu W, He L, Li Y, Tan Y, Zhang F, Xu H. Silencing of lncRNA ZFAS1 inhibits malignancies by blocking Wnt\/\u03b2-catenin signaling in gastric cancer cells. Biosci Biotechnol Biochem. 2018;82:456\u201365.","journal-title":"Biosci Biotechnol Biochem"},{"key":"1837_CR47","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.biopha.2018.09.181","volume":"108","author":"Y Li","year":"2018","unstructured":"Li Y, Lv S, Ning H, Li K, Zhou X, Xv H, Wen H. Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a. Biomed Pharmacother. 2018;108:1775\u201382.","journal-title":"Biomed Pharmacother"},{"key":"1837_CR48","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1080\/15476286.2019.1709296","volume":"17","author":"Z Wang","year":"2020","unstructured":"Wang Z, Wang Q, Xu G, Meng N, Huang X, Jiang Z, Chen C, Zhang Y, Chen J, Li A, Li N, Zou X, Zhou J, Ding Q, Wang S. The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505\/CYLD\/AKT axis in human gastric cancer cells. RNA Biol. 2020;17:1576\u201389.","journal-title":"RNA Biol"},{"key":"1837_CR49","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.1016\/S1470-2045(13)70436-4","volume":"14","author":"L Shen","year":"2013","unstructured":"Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, Park SR, Fujii M, Kang YK, Chen LT. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e535\u2013547.","journal-title":"Lancet Oncol"},{"key":"1837_CR50","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330\u20138.","journal-title":"Nat Rev Cancer"},{"key":"1837_CR51","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/annonc\/mdh264","volume":"15","author":"P Noordhuis","year":"2004","unstructured":"Noordhuis P, Holwerda U, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM, Peters GJ. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol. 2004;15:1025\u201332.","journal-title":"Ann Oncol"},{"key":"1837_CR52","doi-asserted-by":"crossref","unstructured":"Azwar S, Seow HF, Abdullah M, Faisal Jabar M, Mohtarrudin N. Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment. Biology (Basel), 10 (2021).","DOI":"10.3390\/biology10090854"},{"key":"1837_CR53","doi-asserted-by":"publisher","first-page":"999551","DOI":"10.3389\/fimmu.2022.999551","volume":"13","author":"S Dong","year":"2022","unstructured":"Dong S, Zhang S, Zhao P, Lin G, Ma X, Xu J, Zhang H, Hu J, Zou C. A combined analysis of bulk and single-cell sequencing data reveals that depleted extracellular matrix and enhanced immune processes co-contribute to fluorouracil beneficial responses in gastric cancer. Front Immunol. 2022;13:999551.","journal-title":"Front Immunol"},{"key":"1837_CR54","doi-asserted-by":"crossref","unstructured":"Ham IH, Wang L, Lee D, Woo J, Kim TH, Jeong HY, Oh HJ, Choi KS, Kim TM, Hur H. Curcumin inhibits the cancer\u2013associated fibroblast\u2013derived chemoresistance of gastric cancer through the suppression of the JAK\/STAT3 signaling pathway. Int J Oncol, 61 (2022).","DOI":"10.3892\/ijo.2022.5375"},{"key":"1837_CR55","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","volume":"116","author":"NN Danial","year":"2004","unstructured":"Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116:205\u201319.","journal-title":"Cell"},{"key":"1837_CR56","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1470-2045(20)30315-6","volume":"21","author":"YK Kang","year":"2020","unstructured":"Kang YK, Chin K, Chung HC, Kadowaki S, Oh SC, Nakayama N, Lee KW, Hara H, Chung IJ, Tsuda M, Park SH, Hosaka H, Hironaka S, Miyata Y, Ryu MH, Baba H, Hyodo I, Bang YJ, Boku N. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21:1045\u201356.","journal-title":"Lancet Oncol"},{"key":"1837_CR57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.apsb.2016.08.005","volume":"7","author":"J Deng","year":"2017","unstructured":"Deng J. How to unleash mitochondrial apoptotic blockades to kill cancers? Acta Pharm Sin B. 2017;7:18\u201326.","journal-title":"Acta Pharm Sin B"},{"key":"1837_CR58","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.molcel.2006.12.013","volume":"25","author":"Q Bao","year":"2007","unstructured":"Bao Q, Lu W, Rabinowitz JD, Shi Y. Calcium blocks formation of apoptosome by preventing nucleotide exchange in Apaf-1. Mol Cell. 2007;25:181\u201392.","journal-title":"Mol Cell"},{"key":"1837_CR59","doi-asserted-by":"publisher","first-page":"e2201889","DOI":"10.1002\/advs.202201889","volume":"9","author":"Q Wang","year":"2022","unstructured":"Wang Q, Chen C, Xu X, Shu C, Cao C, Wang Z, Fu Y, Xu L, Xu K, Xu J, Xia A, Wang B, Xu G, Zou X, Su R, Kang W, Xue Y, Mo R, Sun B, Wang S. APAF1-Binding Long Noncoding RNA Promotes Tumor Growth and Multidrug Resistance in Gastric Cancer by Blocking Apoptosome Assembly. Adv Sci (Weinh). 2022;9:e2201889.","journal-title":"Adv Sci (Weinh)"},{"key":"1837_CR60","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41416-020-01067-1","volume":"124","author":"J Zhao","year":"2021","unstructured":"Zhao J, Fu X, Chen H, Min L, Sun J, Yin J, Guo J, Li H, Tang Z, Ruan Y, Wang X, Sun Y, Huang L. G3BP1 interacts with YWHAZ to regulate chemoresistance and predict adjuvant chemotherapy benefit in gastric cancer. Br J Cancer. 2021;124:425\u201336.","journal-title":"Br J Cancer"},{"key":"1837_CR61","doi-asserted-by":"publisher","first-page":"102317","DOI":"10.1016\/j.redox.2022.102317","volume":"52","author":"S Ouyang","year":"2022","unstructured":"Ouyang S, Li H, Lou L, Huang Q, Zhang Z, Mo J, Li M, Lu J, Zhu K, Chu Y, Ding W, Zhu J, Lin Z, Zhong L, Wang J, Yue P, Turkson J, Liu P, Wang Y, Zhang X. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol. 2022;52:102317.","journal-title":"Redox Biol"},{"key":"1837_CR62","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.canlet.2014.10.023","volume":"356","author":"H Kim","year":"2015","unstructured":"Kim H, Choi H, Lee SK. Epstein-Barr virus miR-BART20-5p regulates cell proliferation and apoptosis by targeting BAD. Cancer Lett. 2015;356:733\u201342.","journal-title":"Cancer Lett"},{"key":"1837_CR63","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.biocel.2018.06.007","volume":"102","author":"DM Wu","year":"2018","unstructured":"Wu DM, Hong XW, Wang LL, Cui XF, Lu J, Chen GQ, Zheng YL. MicroRNA-17 inhibition overcomes chemoresistance and suppresses epithelial-mesenchymal transition through a DEDD-dependent mechanism in gastric cancer. Int J Biochem Cell Biol. 2018;102:59\u201370.","journal-title":"Int J Biochem Cell Biol"},{"key":"1837_CR64","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1038\/onc.2013.297","volume":"33","author":"Y Shang","year":"2014","unstructured":"Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li K, Zhou L, Sun Y, Li M, Zhou J, An Y, Wu K, Nie Y, Fan D. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2014;33:3267\u201376.","journal-title":"Oncogene"},{"key":"1837_CR65","doi-asserted-by":"publisher","first-page":"e0143716","DOI":"10.1371\/journal.pone.0143716","volume":"10","author":"R Teng","year":"2015","unstructured":"Teng R, Hu Y, Zhou J, Seifer B, Chen Y, Shen J, Wang L. Overexpression of Lin28 Decreases the Chemosensitivity of Gastric Cancer Cells to Oxaliplatin, Paclitaxel, Doxorubicin, and Fluorouracil in Part via microRNA-107. PLoS ONE. 2015;10:e0143716.","journal-title":"PLoS ONE"},{"key":"1837_CR66","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/ijc.25260","volume":"127","author":"W Zhu","year":"2010","unstructured":"Zhu W, Shan X, Wang T, Shu Y, Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 2010;127:2520\u20139.","journal-title":"Int J Cancer"},{"key":"1837_CR67","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1159\/000438524","volume":"37","author":"P Zhu","year":"2015","unstructured":"Zhu P, Zhang J, Zhu J, Shi J, Zhu Q, Gao Y. MiR-429 Induces Gastric Carcinoma Cell Apoptosis Through Bcl-2. Cell Physiol Biochem. 2015;37:1572\u201380.","journal-title":"Cell Physiol Biochem"},{"key":"1837_CR68","doi-asserted-by":"publisher","first-page":"e1766","DOI":"10.1038\/cddis.2015.123","volume":"6","author":"Y An","year":"2015","unstructured":"An Y, Zhang Z, Shang Y, Jiang X, Dong J, Yu P, Nie Y, Zhao Q. miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis. 2015;6:e1766.","journal-title":"Cell Death Dis"},{"key":"1837_CR69","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1177\/1535370217728460","volume":"242","author":"A Korourian","year":"2017","unstructured":"Korourian A, Roudi R, Shariftabrizi A, Madjd Z. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Exp Biol Med (Maywood). 2017;242:1842\u20137.","journal-title":"Exp Biol Med (Maywood)"},{"key":"1837_CR70","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.abb.2019.01.023","volume":"663","author":"KK Sun","year":"2019","unstructured":"Sun KK, Shen XJ, Yang D, Gan MQ, Liu G, Zhang YF, Hua P, Wang HD, Wu XY. MicroRNA-31 triggers G(2)\/M cell cycle arrest, enhances the chemosensitivity and inhibits migration and invasion of human gastric cancer cells by downregulating the expression of zeste homolog 2 (ZH2). Arch Biochem Biophys. 2019;663:269\u201375.","journal-title":"Arch Biochem Biophys"},{"key":"1837_CR71","first-page":"35","volume":"120","author":"A Korourian","year":"2019","unstructured":"Korourian A, Madjd Z, Roudi R, Shariftabrizi A, Soleimani M. Induction of miR-31 causes increased sensitivity to 5-FU and decreased migration and cell invasion in gastric adenocarcinoma. Bratisl Lek Listy. 2019;120:35\u20139.","journal-title":"Bratisl Lek Listy"},{"key":"1837_CR72","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.3892\/mmr.2015.4052","volume":"12","author":"HL Xiong","year":"2015","unstructured":"Xiong HL, Zhou SW, Sun AH, He Y, Li J, Yuan X. MicroRNA\u2013197 reverses the drug resistance of fluorouracil\u2013induced SGC7901 cells by targeting mitogen\u2013activated protein kinase 1. Mol Med Rep. 2015;12:5019\u201325.","journal-title":"Mol Med Rep"},{"key":"1837_CR73","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00705-016-3109-z","volume":"162","author":"H Choi","year":"2017","unstructured":"Choi H, Lee SK. TAX1BP1 downregulation by EBV-miR-BART15-3p enhances chemosensitivity of gastric cancer cells to 5-FU. Arch Virol. 2017;162:369\u201377.","journal-title":"Arch Virol"},{"key":"1837_CR74","first-page":"1370","volume":"40","author":"H Nie","year":"2018","unstructured":"Nie H, Mu J, Wang J, Li Y. miR\u2013195\u20135p regulates multi\u2013drug resistance of gastric cancer cells via targeting ZNF139. Oncol Rep. 2018;40:1370\u20138.","journal-title":"Oncol Rep"},{"key":"1837_CR75","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1159\/000490871","volume":"47","author":"LQ Li","year":"2018","unstructured":"Li LQ, Pan D, Chen Q, Zhang SW, Xie DY, Zheng XL, Chen H. Sensitization of Gastric Cancer Cells to 5-FU by MicroRNA-204 Through Targeting the TGFBR2-Mediated Epithelial to Mesenchymal Transition. Cell Physiol Biochem. 2018;47:1533\u201345.","journal-title":"Cell Physiol Biochem"},{"key":"1837_CR76","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3727\/096504018X15193469240508","volume":"27","author":"L Jiang","year":"2018","unstructured":"Jiang L, Yang W, Bian W, Yang H, Wu X, Li Y, Feng W, Liu X. MicroRNA-623 Targets Cyclin D1 to Inhibit Cell Proliferation and Enhance the Chemosensitivity of Cells to 5-Fluorouracil in Gastric Cancer. Oncol Res. 2018;27:19\u201327.","journal-title":"Oncol Res"},{"key":"1837_CR77","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11010-014-2028-0","volume":"392","author":"L Xie","year":"2014","unstructured":"Xie L, Zhang Z, Tan Z, He R, Zeng X, Xie Y, Li S, Tang G, Tang H, He X. MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer. Mol Cell Biochem. 2014;392:153\u20139.","journal-title":"Mol Cell Biochem"},{"key":"1837_CR78","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12943-017-0743-3","volume":"16","author":"H YiRen","year":"2017","unstructured":"YiRen H, YingCong Y, Sunwu Y, Keqin L, Xiaochun T, Senrui C, Ende C, XiZhou L, Yanfan C. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2017;16:174.","journal-title":"Mol Cancer"},{"key":"1837_CR79","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1186\/1471-2407-14-932","volume":"14","author":"Y Han","year":"2014","unstructured":"Han Y, Ye J, Wu D, Wu P, Chen Z, Chen J, Gao S, Huang J. LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. BMC Cancer. 2014;14:932.","journal-title":"BMC Cancer"},{"key":"1837_CR80","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver BA. How Taxol\/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677\u201381.","journal-title":"Mol Biol Cell"},{"key":"1837_CR81","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12013-014-0450-2","volume":"72","author":"B Jin","year":"2015","unstructured":"Jin B, Liu Y, Wang H. Antagonism of miRNA-21 Sensitizes Human Gastric Cancer Cells to Paclitaxel. Cell Biochem Biophys. 2015;72:275\u201382.","journal-title":"Cell Biochem Biophys"},{"key":"1837_CR82","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.2147\/OTT.S110923","volume":"9","author":"B Shen","year":"2016","unstructured":"Shen B, Yu S, Zhang Y, Yuan Y, Li X, Zhong J, Feng J. miR-590-5p regulates gastric cancer cell growth and chemosensitivity through RECK and the AKT\/ERK pathway. Onco Targets Ther. 2016;9:6009\u201319.","journal-title":"Onco Targets Ther"},{"key":"1837_CR83","first-page":"326","volume":"54","author":"M Wang","year":"2019","unstructured":"Wang M, Qiu R, Yu S, Xu X, Li G, Gu R, Tan C, Zhu W, Shen B. Paclitaxel\u2013resistant gastric cancer MGC\u2013803 cells promote epithelial\u2013to\u2013mesenchymal transition and chemoresistance in paclitaxel\u2013sensitive cells via exosomal delivery of miR\u2013155\u20135p. Int J Oncol. 2019;54:326\u201338.","journal-title":"Int J Oncol"},{"key":"1837_CR84","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00280-013-2108-y","volume":"71","author":"H Wu","year":"2013","unstructured":"Wu H, Huang M, Lu M, Zhu W, Shu Y, Cao P, Liu P. Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol. 2013;71:1159\u201371.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1837_CR85","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.3892\/ol.2017.6041","volume":"13","author":"L Li","year":"2017","unstructured":"Li L, Wu C, Zhao Y. miRNA-34a enhances the sensitivity of gastric cancer cells to treatment with paclitaxel by targeting E2F5. Oncol Lett. 2017;13:4837\u201342.","journal-title":"Oncol Lett"},{"key":"1837_CR86","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1111\/jcmm.13114","volume":"21","author":"Z Zou","year":"2017","unstructured":"Zou Z, Zou R, Zong D, Shi Y, Chen J, Huang J, Zhu J, Chen L, Bao X, Liu Y, Liu W, Huang W, Hu J, Chen Z, Lao X, Chen C, Huang X, Lu Y, Ni X, Fang D, Wu D, Lu S, Jiang M, Qiu C, Wu Y, Qiu Q, Dong Y, Su Y, Zhao C, Zhong Z, Cai J, Liang Y. miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression. J Cell Mol Med. 2017;21:1929\u201343.","journal-title":"J Cell Mol Med"},{"key":"1837_CR87","doi-asserted-by":"crossref","unstructured":"Liu YY, Zhang LY, Du WZ. Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through the regulation of ZEB1 expression by sponging miR-124-3p. Biosci Rep, 39 (2019).","DOI":"10.1042\/BSR20193045"},{"key":"1837_CR88","doi-asserted-by":"publisher","first-page":"153487","DOI":"10.1016\/j.prp.2021.153487","volume":"224","author":"N Zhou","year":"2021","unstructured":"Zhou N, Wang W, Xu C, Yu W. Circular RNA PLEC acts as a sponge of microRNA-198 to promote gastric carcinoma cell resistance to paclitaxel and tumorigenesis. Pathol Res Pract. 2021;224:153487.","journal-title":"Pathol Res Pract"},{"key":"1837_CR89","doi-asserted-by":"publisher","first-page":"7226","DOI":"10.1002\/jcb.26901","volume":"119","author":"H Wang","year":"2018","unstructured":"Wang H, Qin R, Guan A, Yao Y, Huang Y, Jia H, Huang W, Gao J. HOTAIR enhanced paclitaxel and doxorubicin resistance in gastric cancer cells partly through inhibiting miR-217 expression. J Cell Biochem. 2018;119:7226\u201334.","journal-title":"J Cell Biochem"},{"key":"1837_CR90","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2147\/OTT.S68854","volume":"7","author":"J Ding","year":"2014","unstructured":"Ding J, Li D, Gong M, Wang J, Huang X, Wu T, Wang C. Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer. Onco Targets Ther. 2014;7:1625\u201330.","journal-title":"Onco Targets Ther"},{"key":"1837_CR91","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1200\/JCO.2014.60.1799","volume":"33","author":"MA Shah","year":"2015","unstructured":"Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol. 2015;33:1760\u20139.","journal-title":"J Clin Oncol"},{"key":"1837_CR92","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.tree.2011.01.002","volume":"26","author":"AF Caulin","year":"2011","unstructured":"Caulin AF, Maley CC. Peto\u2019s Paradox: evolution\u2019s prescription for cancer prevention. Trends Ecol Evol. 2011;26:175\u201382.","journal-title":"Trends Ecol Evol"},{"key":"1837_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/417048","volume":"66","author":"GC Williams","year":"1991","unstructured":"Williams GC, Nesse RM. The dawn of Darwinian medicine. Q Rev Biol. 1991;66:1\u201322.","journal-title":"Q Rev Biol"},{"key":"1837_CR94","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrc2071","volume":"7","author":"M Greaves","year":"2007","unstructured":"Greaves M. Darwinian medicine: a case for cancer. Nat Rev Cancer. 2007;7:213\u201321.","journal-title":"Nat Rev Cancer"},{"key":"1837_CR95","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fphar.2013.00028","volume":"4","author":"H Zahreddine","year":"2013","unstructured":"Zahreddine H, Borden KL. Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 2013;4:28.","journal-title":"Front Pharmacol"},{"key":"1837_CR96","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1245\/s10434-006-9239-x","volume":"14","author":"GC Cesana","year":"2007","unstructured":"Cesana GC, Romano F, Piacentini G, Scotti M, Brenna A, Bovo G, Vaghi M, Aletti G, Caprotti R, Kaufman H, Uggeri F. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis. Ann Surg Oncol. 2007;14:1295\u2013304.","journal-title":"Ann Surg Oncol"},{"key":"1837_CR97","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3892\/ijo_00000722","volume":"37","author":"T Tanaka","year":"2010","unstructured":"Tanaka T, Bai T, Toujima S. Establishment and characterization of monoclonal 5-fluorouracil-resistant cell lines derived from human endometrial adenocarcinoma. Int J Oncol. 2010;37:731\u20136.","journal-title":"Int J Oncol"},{"key":"1837_CR98","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.3748\/wjg.v16.i18.2291","volume":"16","author":"Y Zhou","year":"2010","unstructured":"Zhou Y, Ling XL, Li SW, Li XQ, Yan B. Establishment of a human hepatoma multidrug resistant cell line in vitro. World J Gastroenterol. 2010;16:2291\u20137.","journal-title":"World J Gastroenterol"},{"key":"1837_CR99","first-page":"5902","volume":"54","author":"SP Cole","year":"1994","unstructured":"Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994;54:5902\u201310.","journal-title":"Cancer Res"},{"key":"1837_CR100","doi-asserted-by":"publisher","first-page":"8822","DOI":"10.1073\/pnas.91.19.8822","volume":"91","author":"GJ Zaman","year":"1994","unstructured":"Zaman GJ, Flens MJ, van Leusden MR, de Haas M, M\u00fclder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A. 1994;91:8822\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1837_CR101","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/sj.bjc.6600305","volume":"86","author":"JH Choi","year":"2002","unstructured":"Choi JH, Lim HY, Joo HJ, Kim HS, Yi JW, Kim HC, Cho YK, Kim MW, Lee KB. Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer. 2002;86:1578\u201385.","journal-title":"Br J Cancer"},{"key":"1837_CR102","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s002689900301","volume":"21","author":"WH Isacoff","year":"1997","unstructured":"Isacoff WH, Borud K. Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview. World J Surg. 1997;21:748\u201362.","journal-title":"World J Surg"},{"key":"1837_CR103","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejphar.2010.06.069","volume":"644","author":"O Weso\u0142owska","year":"2010","unstructured":"Weso\u0142owska O, Wi\u015bniewski J, Sroda K, Krawczenko A, Bielawska-Pohl A, Paprocka M, Du\u015b D, Michalak K. 8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1. Eur J Pharmacol. 2010;644:32\u201340.","journal-title":"Eur J Pharmacol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01837-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01837-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01837-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:01:20Z","timestamp":1790719280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01837-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1837"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01837-9","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"30 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"98"}}